论文部分内容阅读
目的:观察荷丹片联合阿托伐他汀治疗冠心病的临床治疗效果以其为临床诊疗提供参考。方法:分析2015年1月—2016年1月在我院接受诊疗的冠心病(稳定性心绞痛)患者的资料。依据治疗药物的不同将患者分为观察组(阿托伐他汀+荷丹片)及对照组(阿托伐他汀)。对比两组患者治疗期12个月内心绞痛的累积发生率并检测相关血液学指标的改变。结果:本研究共纳入观察组41例,对照组44例。观察组治疗期间心绞痛的累积发生率显著低于对照组(14.63%,6/41 vs 36.36%,16/44;Log-rankχ~2=5.619,P=0.018)。治疗后,观察组与对照组TC、TG、LDL-c水平均显著降低(P<0.05),但观察组低于对照组患者(P<0.05)。治疗后,两组患者治疗后HDL-c水平均显著升高(P<0.05),但观察组高于对照组患者(P<0.05)。治疗后,观察组与对照组CRP、MMP-1、PAPP-A水平均显著降低(P<0.05),但观察组低于对照组患者(P<0.05)。结论:联合使用荷丹片可显著降低冠心病患者心绞痛发作频率,可能与其调控血脂、抗炎及提高动脉粥样斑块稳定等疗效有关。
Objective: To observe the therapeutic effect of holtein combined with atorvastatin in the treatment of coronary heart disease (CHD) and provide reference for clinical diagnosis and treatment. Methods: The data of patients with coronary heart disease (stable angina) admitted to our hospital from January 2015 to January 2016 were analyzed. The patients were divided into observation group (atorvastatin + holtein) and control group (atorvastatin) according to the different therapeutic drugs. The cumulative incidence of angina pectoris within 12 months of treatment in both groups was compared and the changes of related hematological parameters were examined. Results: In this study, 41 cases were included in the observation group and 44 cases in the control group. The incidence of angina pectoris in the observation group was significantly lower than that in the control group (14.63%, 6/41 vs 36.36%, 16/44; Log-rankχ 2 = 5.619, P = 0.018). After treatment, the levels of TC, TG and LDL-c in the observation group and the control group were significantly decreased (P <0.05), but the observation group was lower than the control group (P <0.05). After treatment, HDL-c levels in both groups were significantly increased (P <0.05), but the observation group was higher than the control group (P <0.05). After treatment, the levels of CRP, MMP-1 and PAPP-A in observation group and control group were significantly decreased (P <0.05), but the observation group was lower than the control group (P <0.05). CONCLUSION: The combination of Houdan tablets can significantly reduce the frequency of angina pectoris in patients with coronary heart disease, which may be related to its effects on the regulation of blood lipids, anti-inflammatory and atherosclerotic plaque stabilization.